Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

S. A. Long,Mary Rieck,Srinath Sanda,Jennifer Bollyky,P. L. Samuels,Robin Goland,Andrew Ahmann,Alex Rabinovitch,Sudeepta Aggarwal,D. Phippard,Laurence A. Turka,Mario R. Ehlers,Peter Bianchine,Karen D. Boyle,S. A. Adah,Jeffrey A. Bluestone,Jane H. Buckner,Carla J. Greenbaum

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

2013

S. A. Long
Mary Rieck
Srinath Sanda
Jennifer Bollyky
P. L. Samuels
Robin Goland
Andrew Ahmann
Alex Rabinovitch
Sudeepta Aggarwal
D. Phippard
Laurence A. Turka
Mario R. Ehlers
Peter Bianchine
Karen D. Boyle
S. A. Adah
Jeffrey A. Bluestone
Jane H. Buckner
Carla J. Greenbaum

Author(s): Long, SA; Rieck, M; Sanda, S; Bollyky, JB; Samuels, PL; Goland, R; Ahmann, A; Rabinovitch, A; Aggarwal, S; Phippard, D; Turka, LA; Ehlers, MR; Bianchine, PJ; Boyle, KD; Adah, SA; Bluestone, JA; Buckner, JH; Greenbaum, CJ

Keywords:

Endocrinology
Cell
Internal medicine
Diabetes mellitus
Type 1 diabetes
Combination therapy
Medicine
β cell function
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations